Bone marrow hemodilution assessment in multiple myeloma MRD by next generation flow cytometry - a mini review - Takeaway - MDSpire

Bone marrow hemodilution assessment in multiple myeloma MRD by next generation flow cytometry - a mini review

Share

  • 1

    Bone marrow hemodilution can lead to false negative results in measurable residual disease assessments in multiple myeloma.

  • 2

    Next Generation Flow Cytometry is preferred for MRD identification due to its cost-effectiveness and ability to evaluate hemodilution.

  • 3

    Hemodilution significantly impacts MRD evaluation in multiple myeloma due to the heterogeneous distribution of plasma cells.

  • 4

    Mast cells, nucleated red blood cells, and B cell progenitors are key cellular subpopulations used to assess hemodilution.

  • 5

    A combined evaluation of multiple cellular parameters is recommended for more reliable hemodilution assessments in multiple myeloma.

Original Source(s)

Related Content